Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors

(2015) C. P. Lee et al.   ONCOLOGIST

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

(2013) B. Kutluk Cenik et al.   MOLECULAR CANCER THERAPEUTICS

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

(2011) G Bousquet et al.   BRITISH JOURNAL OF CANCER

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

(2011) Peter Stopfer et al.   XENOBIOTICA

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

(2011) Bruno Gori et al.   Therapeutics and Clinical Risk Management

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2010) I. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH